Corrects headline and story to say the treatment will be launched in 2025, not 2026
March 10 (Reuters) - Eli Lilly LLY.N plans to launch its blockbuster diabetes and weight-loss drug, Mounjaro, in countries like China, India, Brazil and Mexico in 2025, Chief Financial Officer Lucas Montarce said on Monday.
"The size is significant. We're talking about 900 million patients that could benefit from Mounjaro," Montarce said at the Leerink Partners Global Healthcare Conference.
Global demand for Lilly's and Danish rival Novo Nordisk's NOVOb.CO diabetes and weight-loss drugs has been extraordinary, with the two companies delaying their entry into new and emerging markets until they scaled up supply.
Mounjaro, chemically known as tirzepatide, is currently sold in the UK and Europe under the same brand name for both diabetes and weightloss. However, it is sold under the brand name Zepbound for obesity in the U.S.
The drug received approval from Chinese regulators last year.
In February last year, Lilly CEO David Ricks told Reuters that it expects to launch Mounjaro, in India as early as next year.
(Reporting by Sriparna Roy and Christy Santhosh in Bengaluru; Editing by Leroy Leo)
((Sriparna.Roy@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.